CClinicalTrials.gg
CompletedNCT04423783Updated Nov 8, 2024

Gamification in the Treatment of Spider Phobia

An interventional study of 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) and Therapist-guided one-session online exposure therapy according to (Öst, 1989) in Spider Phobia, sponsored by Anke Haberkamp. Completed at 2 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Anke Haberkamp · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Mobile applications are more and more considered when implementing programs for treating mental disorders. The study aims to reduce avoidance and fear of spiders in spider-fearful individuals by combining exposure principles with gamification elements (e.g. narrative background, level progression, points, feedback). We investigate the efficacy of the gamified app in a remote online-therapy context.

02

Conditions studied

  • Spider Phobia

Browse trials for

Keywords

  • Gamification
  • Anxiety Disorder
  • Avoidance
  • App
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Participants must

  • be 18 years or older,
  • SPQ score ≥ 14
  • BDI-II score ≤ 18

Exclusion criteria

Exclusion Criteria:

Participants will be deemed ineligible if they do not meet the above inclusion criteria or

  • are allergic to spiders or bee stings,
  • are currently undergoing psychotherapeutic and/or psychopharmacological treatments,
  • are experiencing current psychosis, mania, or substance abuse, or
  • successfully complete 8 or more of 12 possible BAT steps at baseline (to ensure that participants are indeed spider fearful)
  • are at higher risk from Covid-19 or
  • participated in a pilot study in 2019.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Spider gamification app

    Participants play the spider gamification app twice a day for 7 days

    Behavioral: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)

  • Experimental
    Online exposure + spider gamification app

    Participants receive a therapist-guided one-session online exposure therapy and play the spider gamification app twice a day for 7 days

    Behavioral: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) · Behavioral: Therapist-guided one-session online exposure therapy according to (Öst, 1989)

  • Active comparator
    Online exposure + non-spider gamification app

    Participants receive a therapist-guided one-session online exposure therapy and play a non-spider gamification app twice a day for 7 days

    Behavioral: Therapist-guided one-session online exposure therapy according to (Öst, 1989)

Interventions

  • Behavioral7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)

    Confrontation with spiders via gamified app

    Also known as: Spider Gamification App

  • BehavioralTherapist-guided one-session online exposure therapy according to (Öst, 1989)

    Massed exposure therapy over the course of one single session, applied in a remote-online context

    Also known as: Online exposure

05

What researchers measure

Primary outcomes

  1. Change in avoidance behavior (Behavioral Approach Task; BAT)

    Scores range from 0 ("participant refuses to enter the room with spider") to 12 ("participant holds the spider at least for 20 sec").

    Time frame: Baseline; (after one-session exposure if applied); Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

  2. Change in spider fear (Spider Phobia Questionnaire; SPQ)

    The scale ranges from 0-31. High scores reflect high subjective levels and low scores low subjective levels of spider fear.

    Time frame: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

  3. Change in spider fear: Spider-Anxiety Questionnaire (FAS)

    The scale ranges from 0-108. High scores reflect high subjective levels and low scores low subjective levels of spider fear.

    Time frame: Baseline; Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

Secondary outcomes

  1. Change in disgust before and after playing the app

    Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced disgust; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app

    Time frame: Before starting and immediately after completing the game

  2. Change in arousal before and after playing the app

    Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced arousal; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app

    Time frame: Before starting and immediately after completing the game

  3. Change in anxiety before and after playing the app

    Seven-point rating scale scoring from 0 to 6: high scores reflect high levels and low scores low levels of experienced anxiety; participants play twice a day (between 8 - 11 am and 4 - 7 pm); ratings are part of the app

    Time frame: Before starting and immediately after completing the game

Other outcomes

  1. Beck Depression Inventory II (BDI-II)

    Measures severity of depression; The scale ranges from 0-63: 0-13 minimal depressive symptoms; 14-19 mild symptoms; 20-28 moderate symptoms; 29-63 severe symptoms.

    Time frame: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

  2. Brief Symptom Inventory (BSI)

    Measures clinically relevant psychological symptoms.

    Time frame: Baseline, Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

  3. German version of the Client Satisfaction Questionnaire (CSQ-8)

    Standardised satisfaction measurement

    Time frame: (after one-session exposure if applied), Post-treatment (1-week after baseline); 3-week follow-up (4-weeks after baseline)

  4. Mobile Application Rating Scale (MARS)

    Questionnaire assessing the quality of new user-oriented health applications

    Time frame: Post-treatment (1-week after baseline)

06

Study locations

2 sites
  • Philipps University Marburg
    Marburg, Germany
  • Philipps-University Marburg Clinical Psychology and Psychotherapy
    Marburg, Germany
07

References and documents

Individual participant data

Plan to share: Yes — Share anonymized IPD via a general-purpose open-access repository

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04423783
Lead sponsor
Anke Haberkamp
Responsible party
Anke Haberkamp (Principal Investigator, Philipps University Marburg) — Sponsor-investigator
First posted
Jun 9, 2020
Start date
Jul 1, 2020
Primary completion
Aug 31, 2024
Completion
Aug 31, 2024
Last update
Nov 8, 2024

Study contacts

Anke Haberkamp, PhD
principal investigator · Philipps University Marburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion